Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Kweder

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Therapeutic Innovation & Regulatory Science|March 4, 2023
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global AgeShannon Thor, Thorsten Vetter, Anabela Marcal, et al.
Clinical Pharmacology and Therapeutics|January 16, 2023
A Comparison of FDA and EMA Pregnancy and Lactation LabelingDana Kappel, Leyla Sahin, Lynne Yao, et al.
The New England Journal of Medicine|April 20, 2007
Ketek--the FDA perspectiveJanice Soreth, Edward Cox, Sandra Kweder, et al.
Therapeutic Innovation & Regulatory Science|October 28, 2022
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME DesignationsZahra Hanaizi, Sandra Kweder, Shannon Thor, et al.
Pharmacoepidemiology and Drug Safety|July 30, 2013
Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal riskPhoebe G Thorpe, Suzanne M Gilboa, Sonia Hernandez-Diaz, et al.
Clinical Pharmacology and Therapeutics|February 22, 2021
Assuring Access to Safe Medicines in Pregnancy and BreastfeedingJanet Nooney, Shannon Thor, Corinne de Vries, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Therapeutic Innovation & Regulatory Science|March 4, 2023
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global AgeShannon Thor, Thorsten Vetter, Anabela Marcal, et al.
Clinical Pharmacology and Therapeutics|January 16, 2023
A Comparison of FDA and EMA Pregnancy and Lactation LabelingDana Kappel, Leyla Sahin, Lynne Yao, et al.
The New England Journal of Medicine|April 20, 2007
Ketek--the FDA perspectiveJanice Soreth, Edward Cox, Sandra Kweder, et al.
Therapeutic Innovation & Regulatory Science|October 28, 2022
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME DesignationsZahra Hanaizi, Sandra Kweder, Shannon Thor, et al.
Pharmacoepidemiology and Drug Safety|July 30, 2013
Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal riskPhoebe G Thorpe, Suzanne M Gilboa, Sonia Hernandez-Diaz, et al.
Clinical Pharmacology and Therapeutics|February 22, 2021
Assuring Access to Safe Medicines in Pregnancy and BreastfeedingJanet Nooney, Shannon Thor, Corinne de Vries, et al.
Pageof 1